Following the initial screening and in-depth characterization of a range of HSP90 inhibitors, primary cultures from two distinct metastatic sites (lung and diaphragm) of a patient with stage IV ACC were treated for 72 h with 0.2 μM luminespib and ganetespib, respectively. The gene discussed is HSP90AA1; the disease is adrenal cortex carcinoma.